Évaluation pharmacoéconomique des anticoagulants dans la prise en charge des thromboses associées au cancer

Abstract

The pharmacoeconomic evaluation of anticoagulants in the management of thrombosis associated with cancer represents a major challenge in oncology. As the life expectancy of cancer patients has increased, so has the risk of thrombotic complications, requiring optimal management of these risks through a multidisciplinary approach involving oncologists, pharmacists and health economists. This study aims to analyse the costs and benefits of different anticoagulants used in cancer patients, focusing on cost-effectiveness and the impact on patients' quality of life and long-term clinical outcomes. In order to determine the most cost-effective anticoagulant in the treatment of cancerassociated thrombosis, we conducted a literature review of several articles (pharmacoeconomic studies) from different countries and health system perspectives comparing different anticoagulants in a variety of settings, methods and conditions.In conclusion, direct oral anticoagulants (DOAC) hold promise for treating cancerassociated thrombosis, but decisions need to consider patients, local costs and economic impact. Further research, including real data and cost analyses, is needed. In Algeria, the lack of pharmacoeconomic studies of anticoagulants in cancer needs to be addressed to improve care, patient outcomes and value for money.